Related Experiment Video
Updated: Aug 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid-lowering therapy following major cardiac events: progress and deficits
A M Mudge1, R Brockett, K F Foxcroft
1Division of Medicine, Royal Brisbane Hospital, Brisbane, QLD.
Objective:
To assess hospital prescribing of lipid-lowering agents in a tertiary hospital, and examine continuation of, or changes to, such therapy in the 6-18 months following discharge.
Design:
Retrospective data extraction from the hospital records of patients admitted from October 1998 to April 1999. These patients and their general practitioners were then contacted to obtain information about ongoing management after discharge.
Setting:
Tertiary public hospital and community.
Participants:
352 patients admitted to hospital with acute myocardial infarction or unstable angina, and their GPs.
Main Outcome Measures:
Percentage of eligible patients discharged on lipid-lowering therapy and percentage of patients continuing or starting such therapy 6-18 months after discharge.
Results:
10% of inpatients with acute coronary syndromes did not have lipid-level estimations performed or arranged during admission. Documentation of lipid levels in discharge summaries was poor. Eighteen per cent of patients with a total serum cholesterol level greater than 5.5 mmol/L did not receive a discharge prescription for a cholesterol-lowering agent. Compliance with treatment on follow-up was 88% in the group discharged on treatment. However, at follow-up, 70% of patients discharged without therapy had not been commenced on lipid-lowering treatment by their GPs.
Conclusions:
Prescribing of lipid-lowering therapy for secondary prevention following acute coronary syndromes remains suboptimal. Commencing treatment in hospital is likely to result in continuing therapy in the community. Better communication of lipid-level results, treatment and treatment aims between hospitals and GPs might encourage optimal treatment practices.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease V: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

